Abstract

AbstractChronic ingestion of the highly active, specific cysteine proteinase inhibitor, E‐64, has a profound effect on Colorado potato beetle (CPB) larval growth, development and survival, as well as on adult fecundity. However, the number of insects surviving to the adult stage did not decrease below 26% with increasing E‐64 concentration above 1.5 μg E‐64 cm−2 leaf surface. The development time to the pupal stage was increased from 13 days, when larvae were reared on control leaves, to 21 days at a concentration of 1.5 μg E‐64 cm−2. The most significant effect of dietary E‐64 was on adult fecundity, with mated females reared on untreated leaves laying an average 62 ± 5.7 eggs daily in the first 10 days, and those maintained on 0.5 μg E‐64 cm−2, laying only 16 ± 2.4 eggs day−1. Females given 1 μg E‐64 cm−2 laid few if any eggs, but started producing egg masses as large as control insects about 5 days after being switched to control leaves. These effects on the insect life cycle were directly related to the degree of inhibition of cysteine proteinase activity in gut extracts. The general proteinase activity in control extracts was 6.5 ± 0.16 units min−1 mg gut−1, which decreased to 1.9 ± 0.16 in guts of insects reared on 1 μg E‐64 cm−2. The proportion of proteinase activity inhibitable by E‐64 decreased from 66% in control guts to 10‐15% in guts from larvae reared on 1 μg E‐64 cm−2. The aspartate proteinase inhibitor, pepstatin, decreased proteinase activity by 35% in control guts. There was no induction of pepstatin‐inhibitable proteinases in response to inhibition by E‐64, and no inhibition of gut enzyme activity by soybean trypsin inhibitor from larvae fed any of the E‐64 concentrations. This study demonstrates that proteinase levels must be significantly reduced to have a pronounced effect on larval growth and survival, while fecundity of mated females is affected by lower concentrations of inhibitor. It also suggests that the CPB may be a difficult pest to control using a more specific, plant‐derived cysteine proteinase inhibitor, such as oryzacystatin.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.